Medtronic (NYSE:MDT) posted its quarterly earnings data on Tuesday. The medical technology company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.15 by $0.07, Morningstar.com reports. Medtronic had a net margin of 10.56% and a return on equity of 12.98%. The company had revenue of $7.48 billion for the quarter, compared to analyst estimates of $7.35 billion. During the same period in the prior year, the company posted $1.07 EPS. The firm’s revenue for the quarter was up 6.1% on a year-over-year basis. Medtronic updated its FY 2019 guidance to $5.10-5.15 EPS and its FY19 guidance to $5.10-5.15 EPS.

NYSE MDT opened at $90.37 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.06 and a current ratio of 2.46. Medtronic has a 52-week low of $76.41 and a 52-week high of $100.15. The company has a market cap of $126.54 billion, a PE ratio of 18.95, a price-to-earnings-growth ratio of 2.49 and a beta of 0.94.

A number of research firms recently weighed in on MDT. Royal Bank of Canada increased their price objective on shares of Medtronic to $109.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 3rd. Oppenheimer reissued a “buy” rating on shares of Medtronic in a research report on Friday, September 21st. Argus increased their price objective on shares of Medtronic from $108.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, October 8th. ValuEngine raised shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Friday, September 7th. Finally, Zacks Investment Research raised shares of Medtronic from a “sell” rating to a “hold” rating in a research report on Thursday, August 23rd. Eight analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $102.58.

In other Medtronic news, Director Richard H. Anderson acquired 2,600 shares of the company’s stock in a transaction dated Thursday, August 23rd. The shares were purchased at an average cost of $95.88 per share, for a total transaction of $249,288.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Richard Kuntz sold 47,176 shares of the stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $95.88, for a total transaction of $4,523,234.88. Following the transaction, the senior vice president now owns 152,579 shares in the company, valued at $14,629,274.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 268,678 shares of company stock worth $25,818,353. Insiders own 0.28% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ballew Advisors Inc bought a new position in shares of Medtronic during the second quarter valued at approximately $100,000. Polaris Greystone Financial Group LLC boosted its stake in shares of Medtronic by 255.1% during the third quarter. Polaris Greystone Financial Group LLC now owns 1,321 shares of the medical technology company’s stock valued at $130,000 after purchasing an additional 949 shares in the last quarter. Fort L.P. bought a new position in shares of Medtronic during the second quarter valued at approximately $121,000. Amussen Hunsaker Associates LLC boosted its stake in shares of Medtronic by 87.4% during the third quarter. Amussen Hunsaker Associates LLC now owns 1,535 shares of the medical technology company’s stock valued at $141,000 after purchasing an additional 716 shares in the last quarter. Finally, Trustcore Financial Services LLC boosted its stake in Medtronic by 97.3% in the second quarter. Trustcore Financial Services LLC now owns 1,760 shares of the medical technology company’s stock valued at $151,000 after acquiring an additional 868 shares in the last quarter. Hedge funds and other institutional investors own 79.56% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/11/20/medtronic-mdt-issues-earnings-results-beats-expectations-by-0-07-eps.html.

Medtronic Company Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Recommended Story: Short Selling

Earnings History for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.